New Wolf admin order expands access to ‘most cost-effective form’ of naloxone
The expanded order gives Pennsylvanians affected by substance use disorder a chance to receive treatment, Gov. Tom Wolf said in a statement.
Wolf admin. adds intramuscular injection to expanded naloxone order
DDAP reports that between November 2017 and March 31, 2022, there have been 22,085 overdose reversals using state-purchased Narcan.
Pa. to start citing unlicensed recovery houses this week
The agency was granted that oversight through a 2017 state law, and licensing applications were made available through DDAP in December 2021.
Bill allowing personal testing equipment, Fentanyl test strips passes House committee
Current state law categorizes “testing equipment used, intended for use or designed for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances” as “drug paraphernalia.”
Pa. residents recovering from substance use disorder deserve safe, supportive housing | Opinion
Everyone’s recovery journey is different; but for many, one of the critical stops following treatment is moving into a recovery house.
State officials launch $10M program to help substance use disorder treatment professionals repay their student loans
The Substance Use Disorder Loan Repayment Program, which is being administered by the Pennsylvania Department of Drug and Alcohol Programs, is accepting applications from treatment professionals as well as case management professionals with outstanding student loan debt.
‘It’s OK to not be OK,’: Wolf admin. highlights mental health, substance use resources for holiday season
In a virtual briefing with reporters Wednesday, Department of Drug and Alcohol Programs Secretary Jen Smith said that the holiday season can be “overwhelming and triggering” for those with substance use disorder.
State officials discuss trauma, substance use among incarcerated women | Friday Morning Coffee
The Pennsylvania Department of Corrections reports that about 66 percent of the women in state correctional institutions (SCIs) are on the DOC mental health roster; more than 50 percent of the women have a history of substance use.
Amid nationwide injectable Naloxone shortage, Pa. entities rely on Narcan supply
Naloxone, an injectable, intramuscular drug approved by the Food and Drug Administration for the rapid reversal of opioid overdoses, has been in scant supply since Pfizer, the drug’s maker, ran into manufacturing issues in 2020, causing the price of the Naloxone to soar even as demand for the drug increased during pandemic-fueled shutdowns, The Guardian reported earlier this month.
Substance use, alcohol consumption rises during pandemic, state officials say
While all of the 2020 data has not been released yet, state health officials said in April that preliminary data show there were at least 422 more overdose deaths in 2020 than in 2019.